360 related articles for article (PubMed ID: 26126972)
1. Prognostic significance of tumor subtypes in male breast cancer: a population-based study.
Leone JP; Leone J; Zwenger AO; Iturbe J; Vallejo CT; Leone BA
Breast Cancer Res Treat; 2015 Aug; 152(3):601-9. PubMed ID: 26126972
[TBL] [Abstract][Full Text] [Related]
2. Overall Survival of Men and Women With Breast Cancer According to Tumor Subtype: A Population-based Study.
Leone J; Zwenger AO; Leone BA; Vallejo CT; Leone JP
Am J Clin Oncol; 2019 Feb; 42(2):215-220. PubMed ID: 30499840
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors in male breast cancer: a population-based study.
Leone JP; Zwenger AO; Iturbe J; Leone J; Leone BA; Vallejo CT; Bhargava R
Breast Cancer Res Treat; 2016 Apr; 156(3):539-548. PubMed ID: 27039306
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of HER2-positive and triple-negative status in small (≤ 1 cm) node-negative breast cancer.
Gorshein E; Klein P; Boolbol SK; Shao T
Clin Breast Cancer; 2014 Oct; 14(5):309-14. PubMed ID: 24703318
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
[TBL] [Abstract][Full Text] [Related]
8. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
9. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
10. Poorer breast cancer survival outcomes in males than females might be attributable to tumor subtype.
Wu Q; Li J; Zhu S; Wu J; Li X; Liu Q; Wei W; Sun S
Oncotarget; 2016 Dec; 7(52):87532-87542. PubMed ID: 27655704
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
12. Tumor subtypes and survival in male breast cancer.
Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
[TBL] [Abstract][Full Text] [Related]
13. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Jin X; Jiang YZ; Chen S; Yu KD; Shao ZM; Di GH
Oncotarget; 2015 Apr; 6(11):9600-11. PubMed ID: 25826079
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of young age (<35 years) by subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based study.
Kim EK; Noh WC; Han W; Noh DY
World J Surg; 2011 Jun; 35(6):1244-53. PubMed ID: 21472372
[TBL] [Abstract][Full Text] [Related]
20. Surgical Management of Breast Cancer in 2010-2011 SEER Registries by Hormone and HER2 Receptor Status.
Lizarraga I; Schroeder MC; Weigel RJ; Thomas A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S566-72. PubMed ID: 25956579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]